New Protein Production Platform

Syngene International, a contract research, development, and manufacturing organization (CRDMO), now offers a new protein production platform aimed at rapid protein synthesis. The platform uses a cell line and transposon-based technology that Syngene licensed from ExcellGene, a Switzerland-based service provider specializing in mammalian cell line development.

The new protein synthesis platform, combined with Syngene’s clone selection and development processes, offers significant improvement in efficiency and precision. The platform offers faster preclinical and clinical development and shorter timelines to product launches, shortening time to market. Advantages include up to 10 weeks reduction in time versus traditional cell line development methods; better predictability and protein yields, with high-titer levels of up to 10 g/L achieved; support for a variety of modalities, including monoclonal antibodies, biosimilars, bispecific antibodies, antibody drug conjugates, and other recombinant proteins. In addition, the platform’s versatility facilitates integration with perfusion and fed-batch manufacturing processes.

Syngene International